![]() 102000034448 gene-regulatory proteins Human genes 0.000 abstract description 10.108091006088 gene-regulatory proteins Proteins 0.000 abstract description 10.210000004879 pulmonary tissue Anatomy 0.000 claims description 6.230000003349 osteoarthritic Effects 0.000 claims description 6.125000004404 heteroalkyl group Chemical group 0.000 claims description 6.230000003247 decreasing Effects 0.000 claims description 8.125000003178 carboxy group Chemical group OC(*)=O 0.000 claims description 8.206010064930 Age-related macular degeneration Diseases 0.000 claims description 20. ![]() 239000008194 pharmaceutical composition Substances 0.000 claims description 22.125000000217 alkyl group Chemical group 0.000 claims description 28.208000002780 Macular Degeneration Diseases 0.000 claims description 32.230000001404 mediated Effects 0.000 claims abstract description 16.230000002685 pulmonary Effects 0.000 claims abstract description 18.201000008482 osteoarthritis Diseases 0.000 claims abstract description 22.210000001519 tissues Anatomy 0.000 claims abstract description 54.150000001875 compounds Chemical class 0.000 claims abstract description 220.125000000623 heterocyclic group Chemical group 0.000 title description 4.230000002401 inhibitory effect Effects 0.000 title abstract description 36.Assignors: DAVID, NATHANIEL Publication of US20200338094A1 publication Critical patent/US20200338094A1/en Status Abandoned legal-status Critical Current Links ![]() ASSIGNMENT OF ASSIGNORS INTEREST (SEE DOCUMENT FOR DETAILS). Assignors: LABERGE, Remi-Martin Assigned to UNITY BIOTECHNOLOGY, INC. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.) Filing date Publication date Priority claimed from US201562113227P external-priority Priority claimed from PCT/US2016/016894 external-priority patent/WO2016127135A1/en Application filed by Buck Institute for Research on Aging, Unity Biotechnology Inc filed Critical Buck Institute for Research on Aging Priority to US16/893,012 priority Critical patent/US20200338094A1/en Assigned to BUCK INSTITUTE FOR RESEARCH ON AGING reassignment BUCK INSTITUTE FOR RESEARCH ON AGING ASSIGNMENT OF ASSIGNORS INTEREST (SEE DOCUMENT FOR DETAILS). Original Assignee Buck Institute for Research on Aging Unity Biotechnology Inc Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.) Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.) Abandoned Application number US16/893,012 Inventor Nathaniel David Remi-Martin Laberge Current Assignee (The listed assignees may be inaccurate. Google Patents Use of a Heterocyclic Bcl-xL Inhibitor and Related Analogs for Removing Senescent Cells in the Treatment of Eye Diseases and Other Age-Related ConditionsÄownload PDF Info Publication number US20200338094A1 US20200338094A1 US16/893,012 US202016893012A US2020338094A1 US 20200338094 A1 US20200338094 A1 US 20200338094A1 US 202016893012 A US202016893012 A US 202016893012A US 2020338094 A1 US2020338094 A1 US 2020338094A1 Authority US United States Prior art keywords compound tissue condition cells independently Prior art date Legal status (The legal status is an assumption and is not a legal conclusion. Google Patents US20200338094A1 - Use of a Heterocyclic Bcl-xL Inhibitor and Related Analogs for Removing Senescent Cells in the Treatment of Eye Diseases and Other Age-Related Conditions US20200338094A1 - Use of a Heterocyclic Bcl-xL Inhibitor and Related Analogs for Removing Senescent Cells in the Treatment of Eye Diseases and Other Age-Related Conditions
0 Comments
Leave a Reply. |
AuthorWrite something about yourself. No need to be fancy, just an overview. ArchivesCategories |